Cancer vaccines: challenges and potential solutions

Hellström, 1969, Cellular im-munity against tumor specific antigens, Adv. Cancer Res., 12, 167, 10.1016/S0065-230X(08)60331-0 Boon, 1992, Toward a genetic analysis of tumor rejection antigens, Ann. Inst. Pasteur Immunol., 58, 177 Hellström, 1995, Can co-stimulated tumor immunity be therapeutically efficacious?, Immunol. Rev., 145, 123, 10.1111/j.1600-065X.1995.tb00079.x Pardoll, 1994, Tumor antigens: a new look for the 1990s, Nature, 369, 357, 10.1038/369357a0 Boon, 1996, Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183, 1173, 10.1084/jem.183.3.725 Hellström, 1989, Oncogeneassociated tumor antigens as targets for immunotherapy, FASEB J., 3, 1715, 10.1096/fasebj.3.6.2649402 Mellins, 1991, A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex, J. Exp. Med., 174, 1607, 10.1084/jem.174.6.1607 Neisig, 1996, Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing, J. Immunol., 156, 3196, 10.4049/jimmunol.156.9.3196 Finn, 1995, MUC-1 epithelial tumor mucin-based immunity and cancer vaccines, Immunol. Rev., 145, 61, 10.1111/j.1600-065X.1995.tb00077.x Linsley, 1993, The role of the CD28 receptor during T cell responses to antigen, Annu. Rev. Immunol., 11, 191, 10.1146/annurev.iy.11.040193.001203 June, 1994, The B7 and CD28 receptor families, Immunol. Today, 15, 321, 10.1016/0167-5699(94)90080-9 Marincola, 1994, Loss of HLA haplotype and B locus down-regulation in melanoma cell lines, J. Immunol., 153, 1225, 10.4049/jimmunol.153.3.1225 Garrido, 1993, Natural history of HLA expression during tumor development, Immunol. Today, 14, 491, 10.1016/0167-5699(93)90264-L Stern, 1994, MHC expression in the natural history of cervical cancer, 162 Wei, 1992, HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides, Nature, 356, 443, 10.1038/356443a0 Restifo, 1993, Identification of human cancers deficient in antigen processing, J. Exp. Med., 177, 265, 10.1084/jem.177.2.265 Lehmann, 1995, Differences in the antigens recognized by cytolytic T cells on successive metastases of a melanoma patient are consistent with immune selection, Eur. J. Immunol., 25, 340, 10.1002/eji.1830250206 Elliott, 1996, Tapping into tumours, Nat. Genet., 13, 139, 10.1038/ng0696-139 Klein, 1960, Further studies on isoantigenic variation in mouse carcinomas and sarcomas, J. Natl. Cancer Inst., 25, 271 Sjögren, 1965, Transplantation methods as a tool for detection of tumor specific antigens, Prog. Exp. Tumor Res., 6, 289, 10.1159/000391374 Berke, 1996, A short peptide eluted from the H-2Kb molecule of a polyomaviruspositive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity, J. Virol., 70, 3093, 10.1128/JVI.70.5.3093-3097.1996 Porgador, 1995, Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases, Cancer Res., 55, 4941 Restifo, 1992, A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability, J. Exp. Med., 175, 1423, 10.1084/jem.175.6.1423 Van den Driessche, 1994, Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens, Int. J. Cancer, 58, 217, 10.1002/ijc.2910580213 Kärre, 1995, Express yourself or die: peptides, MHC molecules, and NK cells, Science, 267, 978, 10.1126/science.7863341 Greenberg, 1991, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv. Immunol., 49, 281, 10.1016/S0065-2776(08)60778-6